Session date 16/june/2016
Session number SS 02
Session title : Screening and vaccination interaction: the current perspective
Presentation title : How to best combine vaccination and screening to optimize cervical cancer prevention: the HPV faster consortium
The risk of cervical cancer incidence and mortality in women that test HPV negative and are vaccinated with a broad spectrum vaccine is probably very low. Under these conditions the requirements for further screening of these women would be very limited ( i.e. nee / twice in a lifetime) necessarily based on HPV tests with different options for triage of HPV positive women and may indeed reach a point in which further screening may not be necessary. The potential of such strategies include the acceleration of the reduction of invasive cervical cancer by several years, the reductions in costs of screening programs and the increased quality of like resulting from a reduction of medical procedures both in diagnostics and therapeutics.
The EU 7TH frame supported a pan European study in with the feasibility and acceptability of one of such strategies is to be tested. 11 countries in Europe with long term experience in HPV research are participants of the effort. The study is stating the field work in February 2016. Specific objectives are to explore how the logistics of HPV screening can be articulated with the logistics of vaccination in each country. How women and health care providers accept the idea of HPV vaccinating adult women and some estimates of compliance and safety.
The European study ( CoheaHr) is part of an international consortium that currently includes studies in Mexico, Australia, Canada and projects in preparation in Colombia, Argentina, Brazil and China.